REBECCA DEPALMA: Open Payments
NPI 1487277489 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$19,189 in 67 payments from 9 companies in 2025. Trend: 2023 $53 · 2024 $0 · 2025 $19,189
Consulting: $6,320Speaker / faculty: $6,000Food & beverage: $3,908Travel & lodging: $2,961
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $9,095 |
| E.R. Squibb & Sons, L.L.C. | 19 | $8,671 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $389 |
| Axsome Therapeutics, Inc. | 4 | $309 |
| Vanda Pharmaceuticals Inc. | 2 | $249 |
| Alkermes, Inc. | 2 | $150 |
| Neurocrine BioSciences, Inc. | 2 | $148 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
Products named: VRAYLAR, COBENFY, CAPLYTA, Auvelity, FANAPT, ARISTADA, INGREZZA, UZEDY.
Industry payments across WA — which companies pay providers there.
